Sistema de Salut de Catalunya
Institut Català de la Salut
[Pal SA] Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. [Powles T] Department of Genitourinary Oncology, Barts Health NHS Trust Saint Bartholomew’s Hospital, London, UK. [Kanesvaran R] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. [Molina-Cerrillo J] Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Feldman DR] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Barata P] Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, OH, USA. [Suarez C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-04-02T12:56:24Z
2025-04-02T12:56:24Z
2025-02-26
Immune checkpoint inhibitor; Non-clear cell renal cell carcinoma; Tyrosine kinase inhibitor
Inhibidor del punt de control immunitari; Carcinoma renal de cèl·lules no clares; Inhibidor de la tirosina cinasa
Inhibidor del punto de control inmunitario; Carcinoma renal de células no claras; Inhibidor de la tirosina quinasa
Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with immune checkpoint inhibitor (ICI) has emerged as an effective treatment strategy, but well-designed, phase III randomized clinical trials are needed to demonstrate superiority over current treatment options. Zanzalintinib is a novel, multi-targeted TKI that has demonstrated promising preclinical anti-tumor activity in combination with ICIs. STELLAR-304 is a phase III trial evaluating first-line zanzalintinib plus nivolumab versus sunitinib in advanced nccRCC. Primary endpoints are progression-free survival and objective response rate. Secondary endpoint is overall survival. To our knowledge, STELLAR-304 is the first phase III study assessing a TKI-ICI combination in nccRCC patients across multiple subtypes.
STELLAR-304 is sponsored by Exelixis, Inc. (Alameda, CA, USA).
Article
Published version
English
Ronyons - Càncer - Tractament; Quimioteràpia combinada; Anticossos monoclonals - Ús terapèutic; Proteïnes quinases - Inhibidors - Ús terapèutic; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors; Other subheadings::Other subheadings::Other subheadings::/antagonists & inhibitors; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Carcinoma, Renal Cell; Other subheadings::Other subheadings::Other subheadings::/drug therapy; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas; Otros calificadores::Otros calificadores::Otros calificadores::/antagonistas & inhibidores; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::carcinoma de células renales; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Taylor & Francis
Future Oncology;21(7)
https://doi.org/10.1080/14796694.2025.2458395
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
